MedTrace Logo

A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient

NCT07649395 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-06-16

No results posted yet for this study

Summary

To explore the early intervention timing of recombinant human thrombopoietin (rhTPO) for cancer treatment-induced thrombocytopenia (CTIT) in cervical squamous cell carcinoma (CSCC) patients during concurrent chemoradiotherapy.

Conditions

  • Cervical Squamous Cell Carcinoma

Interventions

DRUG

rhTPO

receiving rhTPO treatment when they occurred G1(100×109/L\>PLT(Platelet)\>75×109/L) CTIT at first presentation during CCRT

DRUG

rhTPO

receiving rhTPO treatment when they occurred G1(75×109/L\>PLT\>50×109/L) CTIT at first presentation during CCRT

Sponsors & Collaborators

  • Mei Feng

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07649395 on ClinicalTrials.gov